Anemia and Iron deficiency in heart failure

Current Heart Failure Reports

Volumn 9, Issue 4, 2012, Pages 319-327

  Gunawardena, Shanti ^a   Dunlap, Mark E ^a  

^a Western Reserve University ^*  (United States)

Author keywords

Anemia; Erythropoietin stimulating agents; Heart failure; Intravenous iron; Iron deficiency

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; IRON; METOPROLOL; VALSARTAN;

ANEMIA; ARTICLE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODILUTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; PLEIOTROPY; PREVALENCE; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT;

ANEMIA; COMORBIDITY; ERYTHROPOIETIN; HEART FAILURE; HEMATINICS; HUMANS; IRON; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872177889     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0112-x     Document Type: Article

References (78)

1. Roger VL, et al. Heart disease and stroke statistics -2012 update: a report from the American Heart Association. Circulation. 2012;125 (1):e2-e220.
2. Silverberg DS, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35(7):1737-44.
3. Henke M, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362(9392):1255-60.
4. Leyland-Jones B, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960-72.
5. Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-98.
6. Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-32.
7. Anand IS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005;112(8):1121-7. (Pubitemid 41216118)
8. O'Meara E, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113 (7):986-94.
9. Adams Jr KF, et al. Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. Am Heart J. 2009;157(5):926-32.
10. Kosiborod M, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med. 2005;165(19):2237-44.
11. Go AS, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006;113(23):2713-23.
12. Dunlay SM, et al. Anemia and heart failure: a community study. Am J Med. 2008;121(8):726-32.
13. Tang WH, Yeo PS. Epidemiology of anemia in heart failure. Heart Fail Clin. 2010;6(3):271-8.
14. Groenveld HF, et al. Anemia and mortality in heart failure patients a systematic review and meta-Analysis. J Am Coll Cardiol. 2008;52 (10):818-27.
15. Berry C, et al. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J. 2006;151 (6):1313-21.
16. Tang WH, et al. Evaluation and long-Term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51(5):569-76.
17. Ishani A, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005;45(3):391-9. (Pubitemid 40186790)
18. Komajda M, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27(12):1440-6. (Pubitemid 43998078)
19. Salisbury AC, Kosiborod M. Outcomes associated with anemia in patients with heart failure. Heart Fail Clin. 2010;6(3):359-72.
20. Peterson PN, et al. Association of longitudinal measures of hemoglobin and outcomes after hospitalization for heart failure. Am Heart J. 2010;159(1):81-9.
21. Waldum B, et al. Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J Am Coll Cardiol. 2012;59(4):371-8. This registry of 4144 chronic heart failure patients demonstrated that anemia was strongly associated with increased mortality. Yet, the study identified two subpopulations of patients in whom anemia was not a predictor of allcause mortality.
22. Kalra PR, et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet. 2003;362(9379):211-2. (Pubitemid 36859939)
23. Maraldi C, et al. Anemia, physical disability, and survival in older patients with heart failure. J Card Fail. 2006;12(7):533-9. (Pubitemid 44316922)
24. Young JB, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101(2):223-30.
25. Anand IS. Pathophysiology of anemia in heart failure. Heart Fail Clin. 2010;6(3):279-88.
26. Jankowska EA, Ponikowski. Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin. 2010;6 (3):295-304.
27. Le Jemtel TH, Arain S. Mediators of anemia in chronic heart failure. Heart Fail Clin. 2010;6(3):289-93.
28. Freudenthaler SM, et al. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest. 1999;29(10):816-23.
29. Opasich C, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232-7. (Pubitemid 41541385)
30. Belonje AM, et al. Erythropoietin in chronic heart failure. Congest Heart Fail. 2007;13(5):289-92.
31. Belonje AM, et al. Endogenous erythropoietin and outcome in heart failure. Circulation. 2010;121(2):245-51.
32. van der Meer P, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44(1):63-7. (Pubitemid 38968458)
33. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17-25.
34. Testa M, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28(4):964-71.
35. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23.
36. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107(2):223-5. (Pubitemid 36135214)
37. Okonko DO, et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241-51. This paper demonstrates how the use of three frequently available indices (TSAT, ferritin, and TIBC) permits the biochemically meaningful discrimination between absolute iron deficiency, functional iron deficiency (ACD), and coexisting absolute + functional iron deficiency.
38. Nanas JN, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12):2485-9. (Pubitemid 44881220)
39. Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. 2008;13(4):379-86.
40. Mrug M, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100(9):2310-4. (Pubitemid 27500154)
41. Terrovitis JV, et al. Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril. J Heart Lung Transplant. 2006;25 (3):333-8. (Pubitemid 43290665)
42. Androne AS, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107(2):226-9.
43. Marques JS. Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists? Congest Heart Fail. 2012;18(1):1-3.
44. van Veldhuisen DJ, et al. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8(9):485-93.
45. Van Wyck DB, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysisdependent CKD. Kidney Int. 2005;68(6):2846-56.
46. Besarab A, Horl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009;14 Suppl 1:22-33.
47. van der Meer P, et al. Erythropoietin treatment in patients with chronic heart failure: a meta-Analysis. Heart. 2009;95(16):1309-14.
48. Drueke TB, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355 (20):2071-84.
49. Szczech LA, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010;77(3):239-46. This secondary analysis of the CHOIR trial did not demonstrate an increased risk of adverse events for patients with a history of heart failure who were treated with the higher hemoglobin target of 13.5 g/l as compared to those with a target of 11.3 g/l.
50. Desai A, et al. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-Analysis. Eur J Heart Fail. 2010;12(9):936-42. This meta-Analysis of ESA treatment trials that included the subroup of patients with heart failure in the TREAT trial demonstrated that ESAs had a neutral effect on heart failure outcomes.
51. Ghali JK, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117(4):526-35.
52. Toblli JE, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657-65.
53. Okonko DO, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103-12.
54. Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.
55. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141(1):14-31.
56. Rastogi S, et al. Darbepoetin-Alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure. Am J Physiol Heart Circ Physiol. 2008;295(6):H2475-82.
57. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17(20):6373-80.
58. Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res. 2012.
59. Parsa CJ, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112(7):999-1007.
60. Solomon SD, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146-55.
61. AaproM. et al. Effects of erythropoietin receptors and erythropoiesisstimulating agents on disease progression in cancer. Br J Cancer. 2012.
62. Barbera L, Thomas G. Erythropoiesis stimulating agents, thrombosis and cancer. Radiother Oncol. 2010;95(3):269-76.
63. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008;13(4):387-92.
64. McMurray JJ, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009;11 (8):795-801.
65. van der Meer P, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46(1):125-33.
66. Hirata A, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006;48(1):176-84.
67. Palazzuoli A, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-Type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J. 2007;154(4):645 e9-15.
68. Brines M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101(41):14907-12.
69. Fiordaliso F, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2005;102(6):2046-51.
70. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52(7):501-11.
71. Jankowska EA, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31 (15):1872-80. Prevalence of iron deficiency in patients with heart failure is typically discussed in the context of anemia. To our knowledge, this is the first study to provide an estimate of the prevalence of iron deficiency in patients with chronic systolic heart failure with or without anemia. Iron deficiency, regardless of the anemia status was shown to be an independent predictor of adverse outcomes.
72. Dong F, et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond). 2005;109(3):277-86.
73. Silverberg DS, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37(7):1775-80.
74. Mancini DM, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107(2):294-9. (Pubitemid 36135227)
75. Palazzuoli A, et al. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. J Cardiovasc Pharmacol. 2009;53(6):462-7.
76. Ponikowski P, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49(7):753-62.
77. van Veldhuisen DJ, et al. Randomized, double-blind, placebocontrolled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28(18):2208-16.
78. Parissis JT, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155(4):751 e1-7.